Trial reportPharmaceutical research2025
Single- and Multiple-dose Pharmacokinetics, Excretion, Metabolism, and Safety of the Antivirulence Agent Fluorothiazinone in Healthy Adults.
Trial report in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionFluorothiazinone (FT) is a novel antivirulence agent formulated as an immediate-release uncoated tablet, with demonstrated efficacy and safety against infections caused by drug-resistant Gram-negative bacteria. In this study, we evaluated the pharmacokinetics, excretion, metabolism, and safety of FT in healthy adults under single- and multiple-dose regimens.
methodsIn a randomized study, participants received either a single 1800 mg oral dose of FT or multiple doses according to one of the following regimens: two doses within one day (900 or 1200 mg every 12 h) or 14 doses across 7 days (900 mg every 12 h). Pharmacokinetics, excretion and metabolic profiles were assessed using serial blood and urine sampling.
resultsTwenty-nine participants completed the study. Dividing the total daily dose into two equal administrations extended FT's half-life and systemic exposure, representing the optimal dosing strategy. Steady-state pharmacokinetics were observed after 7 days of dosing, indicating extensive tissue distribution. Urinary recovery of unmetabolized FT was low, and identified metabolites are presented. Both single and multiple doses were well tolerated.
conclusionFT, administered orally, was safe and well tolerated in healthy adults in both single and repeated dosing regimens. The pharmacokinetic data support the continued clinical development of FT, including its use in future phase II and III trials. FT's lack of impact on normal intestinal microflora further substantiates its potential as an antivirulence therapy.
Indexed as
Identifiers
41034676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.